Concord Biotech Limited shareholders approved all six resolutions tabled at its 41st Annual General Meeting (AGM) held on July 31, 2026, including a critical special resolution to expand lending capabilities to its group companies. The approval of enhanced limits for advancing loans, providing guarantees, and securities to subsidiaries, associates, and joint venture companies marks a key strategic move for the biotechnology firm, enabling greater financial flexibility within its corporate structure pursuant to Section 185 of the Companies Act, 2013.

The meeting, conducted via Video Conferencing/Other Audio Visual Means (VC/OAVM), saw substantial participation through remote e-voting. Ashish Shah of Ashish Shah & Associates served as the scrutinizer for the proceedings, submitting his consolidated report on July 31, 2026, in compliance with Section 108 of the Companies Act, 2013 and Rule 20(xi) of the Companies (Management and Administration) Rules, 2014. Central Depository Services (India) Limited (CDSL) facilitated the remote e-voting process, which remained open from July 28, 2026, to July 30, 2026.

Voting Results Overview

A total of 83,770 shareholders were on record as of July 24, 2026. While no shareholders attended in person or via proxy, 38 shareholders participated through VC/OAVM (four promoters and 34 public shareholders). The majority of votes were cast electronically.

Key Observations on Shareholder Sentiment

The most notable divergence in shareholder sentiment occurred regarding the special resolution for enhanced loan limits. Promoter and promoter group shareholders, holding 46,116,608 shares, abstained from voting on this item, citing their interest in the agenda. Consequently, the resolution relied entirely on public shareholder support. Public non-institutional shareholders voted overwhelmingly in favor with 99.99% support, while public institutional shareholders showed mixed sentiment, with only 43.40% voting in favor and 56.60% against. Despite this institutional resistance, the resolution passed with 35,391,774 votes in favor out of 43,353,536 valid votes polled.

In contrast, other resolutions enjoyed near-unanimous support. The adoption of the standalone and consolidated financial statements for the financial year ended March 31, 2026, received 99.69% support. The declaration of dividend was approved with 99.98% affirmative votes. The re-appointment of Mr. Ankur Vaid (DIN: 01857225), who retires by rotation, secured 99.70% support. Similarly, the appointment of Mrs. Ekta Gupta as an independent director was approved with virtually unanimous consent, receiving negligible opposition.

Concord Biotech delivered a robust performance in the latest quarter, reporting a year-on-year increase across all key financial metrics. Standalone net profit climbed to 612M rupees from 425M rupees in the corresponding period of the previous year, while revenue surged to 2.6B rupees compared to 2.04B rupees year-on-year, underscoring the company's consistent growth trajectory in the biopharma segment.

Financial Performance at a Glance

The company's operational efficiency was evident in its EBITDA figures, which rose to 872M rupees from 614M rupees year-on-year. Notably, the EBITDA margin expanded meaningfully to 33.46% from 30.1% in the same period last year, indicating improved cost management and operating leverage. The table below summarises the key financial metrics for the quarter:

Profitability and Margin Expansion

The year-on-year improvement in EBITDA margin—from 30.1% to 33.46%—highlights Concord Biotech's ability to scale revenues while maintaining disciplined cost controls. The standalone net profit growth from 425M rupees to 612M rupees further reinforces the strength of the company's earnings profile during the quarter. Revenue expansion of approximately 2.6B rupees against 2.04B rupees in the prior year period reflects healthy demand dynamics across the company's product portfolio.